Participants were European-ancestry smokers randomized in double-blind manner to bupropion or placebo, stratified by gender, current depressive symptoms and nicotine dependence severity, using the urn randomization technique. Ancestry was assessed by self-report of “White, non-Hispanic” racial/ethnic heritage. Patients were randomized to either bupropion (150 mg/day for the first 3 days, followed by 300 mg/day), or matching placebo, for 12 weeks and either cognitive behavioral therapy (CBT) or CBT with additional emphasis on treatment of depressive symptoms (CBT-D) – both of which involved 12 two-hour sessions delivered at one of two sites at regional medical centers assigned at random (see Brown et al. (35) for more details about recruitment and behavioral interventions).
